{"product_id":"epithalon-10mg","title":"Epithalon 10mg","description":"\u003ch2\u003eCompound Overview\u003c\/h2\u003e\n\u003cdiv style=\"background:#eef2fb;border:1px solid #cdd8f0;border-left:4px solid #2f4f9e;border-radius:14px;padding:16px 18px;margin:0 0 22px\"\u003e\n\u003cp style=\"margin:0 0 8px;font-size:15px;color:#2f4f9e;font-weight:600\"\u003eManufacturer-commissioned certificate published — in stock\u003c\/p\u003e\n\u003cp style=\"margin:0;font-size:15px;color:#16201a;line-height:1.65\"\u003eThis Epithalon lot has been \u003cstrong\u003etested by a third-party laboratory\u003c\/strong\u003e. Lot epi10-0626-01 — manufacturer batch CS-ep10-0902, as printed on the certificate — measured \u003cstrong\u003eHPLC 99.004% purity and 11.75 mg content\u003c\/strong\u003e (Janoshik Analytical report #230585, analysed 14 September 2026), and that certificate of analysis — covering identity by mass spectrometry and purity by HPLC — is \u003cstrong\u003epublished on this page\u003c\/strong\u003e. The assay was commissioned by the manufacturer, not by us; our own confirmatory Testides test on this lot is still in progress. We do not borrow another lot's figures to fill the gap. See every published result on our \u003ca href=\"\/pages\/lab-results\"\u003elab results page\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e\n\n\u003cp style=\"margin:0 0 16px;font-size:15px;line-height:1.65;color:#16201a\"\u003e\u003cstrong\u003eEpithalon (also written Epitalon, and known by its sequence code AEDG) is a single synthetic tetrapeptide, Ala-Glu-Asp-Gly, supplied here as lyophilised powder for laboratory research use only.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp style=\"margin:0 0 16px;font-size:15px;line-height:1.65;color:#5a6157\"\u003eEpithalon was designed at the St. Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson and colleagues as a short, chemically defined peptide corresponding to the putative active fragment of \u003cstrong style=\"color:#16201a\"\u003eepithalamin\u003c\/strong\u003e — a polypeptide extract of the bovine pineal gland that the same group had studied since the 1970s. That origin is the single most important thing to hold onto when reading anything written about this compound, because almost every popular summary silently merges the two. Epithalamin is a crude multi-peptide extract; Epithalon is one four-residue molecule. They are not interchangeable, and the distinction decides how much of the published record actually applies to the powder in the vial. The mechanism and evidence sections below keep them separate on purpose, because most vendor pages do not.\u003c\/p\u003e\n\n\u003cp style=\"margin:0 0 16px;font-size:15px;line-height:1.65;color:#5a6157\"\u003eChemically, Epithalon is \u003cstrong style=\"color:#16201a\"\u003eCAS 307297-39-8\u003c\/strong\u003e, molecular formula \u003cstrong style=\"color:#16201a\"\u003eC\u003csub\u003e14\u003c\/sub\u003eH\u003csub\u003e22\u003c\/sub\u003eN\u003csub\u003e4\u003c\/sub\u003eO\u003csub\u003e9\u003c\/sub\u003e\u003c\/strong\u003e, average molecular weight \u003cstrong style=\"color:#16201a\"\u003e390.35 Da\u003c\/strong\u003e, PubChem CID 219042, FDA UNII O65P17785G. The sequence is \u003cspan style=\"font-family:ui-monospace,Menlo,monospace;font-size:15px;color:#16201a\"\u003eH-Ala-Glu-Asp-Gly-OH\u003c\/span\u003e — alanine, glutamic acid, aspartic acid, glycine, free at both the N- and C-termini, with no amidation, no acylation, no non-proteinogenic residues and no modifications of any kind. It is one of the smallest peptides sold as a research reagent: a bare, highly hydrophilic acidic tetrapeptide with a net negative charge at neutral pH from its two carboxylic-acid side chains. There is nothing exotic about the molecule itself. What is contested is what it does.\u003c\/p\u003e\n\n\u003cp style=\"margin:0 0 16px;font-size:15px;line-height:1.65;color:#5a6157\"\u003eEpithalon sits inside a larger idea that is worth stating because it shapes every claim made about the molecule. Khavinson's group built a programme around \u003cstrong style=\"color:#16201a\"\u003eshort \"peptide bioregulators\"\u003c\/strong\u003e — two- to four-residue peptides, each tied to a particular tissue, proposed to carry tissue-specific regulatory information: Epithalon (AEDG) for the pineal gland, Thymalin and the dipeptide Vilon for the thymus, and others for vessels, bone and brain. The organising hypothesis is that these peptides are small enough to enter the cell and the nucleus and to interact directly with DNA, tuning the expression of a narrow set of genes rather than acting at a surface receptor. This is an unusual proposed mechanism, and it is the reason the compound is described as a \"bioregulator\" rather than an agonist or inhibitor. A researcher evaluating Epithalon should treat that whole framework as a hypothesis under test — coherent, internally consistent, and still largely unconfirmed outside the group that proposed it.\u003c\/p\u003e\n\n\u003cp style=\"margin:0 0 16px;font-size:15px;line-height:1.65;color:#5a6157\"\u003eTwo research mechanisms dominate the literature, and both come overwhelmingly from one network of investigators. The first is \u003cstrong style=\"color:#16201a\"\u003etelomere biology\u003c\/strong\u003e. In cultured human somatic cells, Khavinson's group reported that Epithalon induced \u003cstrong style=\"color:#16201a\"\u003etelomerase\u003c\/strong\u003e activity and lengthened telomeres, letting human fetal fibroblasts divide past the classical Hayflick limit (Khavinson et al., \u003cem\u003eBull Exp Biol Med\u003c\/em\u003e 2003;135(6):590-592, PMID 12937682; and 2004;137(5):503-506, PMID 15455129). The second is \u003cstrong style=\"color:#16201a\"\u003epineal and circadian signalling\u003c\/strong\u003e: Epithalon and its parent extract have been reported to restore age-related declines in nocturnal melatonin and to normalise circadian rhythm in aged animals and elderly cohorts. Khavinson's framing is that these short peptides act as \u003cstrong style=\"color:#16201a\"\u003ebioregulators\u003c\/strong\u003e — ligands that reach DNA and modulate gene expression — rather than as receptor-agonist drugs. That model is a hypothesis, not a settled mechanism, and we present it as one.\u003c\/p\u003e\n\n\u003cp style=\"margin:0 0 16px;font-size:15px;line-height:1.65;color:#5a6157\"\u003eThe honest frame matters more here than for almost any compound we list. \u003cstrong style=\"color:#16201a\"\u003eThe great majority of the Epithalon and epithalamin literature originates from a single research group\u003c\/strong\u003e, much of it published in one journal and a substantial portion only in Russian. The long-term human cohort reports that are routinely quoted as evidence for Epithalon used \u003cstrong style=\"color:#16201a\"\u003eepithalamin — the extract — not the isolated synthetic tetrapeptide\u003c\/strong\u003e. There is no well-conducted, independent, blinded, placebo-controlled human trial of synthetic Epithalon, and no published Phase I safety study of it. The most useful recent development is a 2025 independent in-vitro study at Brunel University London (Al-dulaimi et al., \u003cem\u003eBiogerontology\u003c\/em\u003e 2025;26:178) that revisited the telomere question in human cell lines — the first serious replication attempt from outside the originating network, and even its authors confined their conclusions to cell culture. Read the whole record as \u003cstrong style=\"color:#16201a\"\u003ehypothesis-generating preclinical and mechanistic research\u003c\/strong\u003e, not as established biology. Our \u003ca href=\"\/blogs\/research\/epithalon-canada\"\u003eEpithalon research guide\u003c\/a\u003e sets out the evidence claim by claim, including which studies used the extract rather than the peptide.\u003c\/p\u003e\n\n\u003cp style=\"margin:0 0 16px;font-size:15px;line-height:1.65;color:#5a6157\"\u003eEpithalon is \u003cstrong style=\"color:#16201a\"\u003einvestigational and approved nowhere as a medicine\u003c\/strong\u003e. There is no Health Canada authorisation and no Drug Identification Number, no FDA approval and no EMA approval. Health Canada named \u003cstrong style=\"color:#16201a\"\u003eEpitalon specifically\u003c\/strong\u003e, by that spelling, in its public advisory of 9 April 2026 on peptides bought online, stating that such products have not been assessed for safety, efficacy or quality, that they are illegal to sell in Canada, and — the sentence a research vendor is obliged to reproduce rather than hide — that labelling a product \"For Research Use Only\" does not make it legal to use in people. We supply this vial as a laboratory reagent and for no other purpose.\u003c\/p\u003e\n\n\u003cdiv style=\"margin-top:20px;margin-bottom:4px;padding:14px 16px;background:#eef2fb;border-left:4px solid #2f4f9e;border-radius:0 8px 8px 0\"\u003e\u003cp style=\"margin:0;font-size:14px;color:#1a1a1a\"\u003e\u003cstrong\u003eFor laboratory and research use only.\u003c\/strong\u003e Not for human consumption, veterinary use, or therapeutic application. Not approved by Health Canada. We do not provide preparation, dilution or administration guidance for any compound we sell. For related research tools see our \u003ca href=\"\/products\/mots-c-10mg\"\u003eMOTS-C\u003c\/a\u003e and \u003ca href=\"\/products\/ghk-cu-50mg\"\u003eGHK-Cu\u003c\/a\u003e pages, or browse the full \u003ca href=\"\/pages\/peptide-library\"\u003epeptide library\u003c\/a\u003e.\u003c\/p\u003e\u003c\/div\u003e\n\u003ch2\u003eSpecifications\u003c\/h2\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eCompound\u003c\/th\u003e\n\u003ctd\u003eEpithalon, lyophilised powder, research vial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSynonyms \/ development code\u003c\/th\u003e\n\u003ctd\u003eEpitalon; AEDG; Epithalone; Ala-Glu-Asp-Gly; H-Ala-Glu-Asp-Gly-OH. FDA UNII O65P17785G. (Related parent material: epithalamin, a pineal-gland polypeptide extract — a different substance, not sold here)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eCompound class\u003c\/th\u003e\n\u003ctd\u003eSynthetic linear tetrapeptide; pineal peptide \"bioregulator\" of the Khavinson short-peptide family; acidic, unmodified, highly water-soluble\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eCAS number\u003c\/th\u003e\n\u003ctd\u003e307297-39-8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eMolecular formula\u003c\/th\u003e\n\u003ctd\u003eC\u003csub\u003e14\u003c\/sub\u003eH\u003csub\u003e22\u003c\/sub\u003eN\u003csub\u003e4\u003c\/sub\u003eO\u003csub\u003e9\u003c\/sub\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eMolecular weight\u003c\/th\u003e\n\u003ctd\u003e390.35 Da (average)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eSequence\u003c\/th\u003e\n\u003ctd\u003eH-Ala-Glu-Asp-Gly-OH (Ala-Glu-Asp-Gly \/ AEDG); free N- and C-termini, no amidation or acylation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePeptide length\u003c\/th\u003e\n\u003ctd\u003e4 residues (tetrapeptide); no non-proteinogenic residues\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAppearance\u003c\/th\u003e\n\u003ctd\u003eWhite lyophilised solid \/ powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePubChem CID\u003c\/th\u003e\n\u003ctd\u003e219042 (ChemSpider 189872; MeSH C421253; EPA CompTox DTXSID80952957)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eResearch applications\u003c\/th\u003e\n\u003ctd\u003eIn vitro and preclinical reagent for telomerase-activity and telomere-length assays (TRAP, qPCR, Southern\/TRF), replicative-senescence and Hayflick-limit culture models, hTERT and ALT (C-circle, PML-body) readouts, pineal\/melatonin and circadian gene-expression work, antioxidant-enzyme (SOD, glutathione peroxidase) and chromosomal-aberration assays, and comparative short-regulatory-peptide pharmacology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eAssay status\u003c\/th\u003e\n\u003ctd\u003eAssayed by HPLC at Janoshik Analytical (#230585, analysed 14 September 2026), commissioned by the manufacturer; certificate published; our own Testides confirmation in progress\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003ePurity label\u003c\/th\u003e\n\u003ctd\u003eHPLC 99.004% (Janoshik #230585, manufacturer-commissioned); COA published, our own Testides confirmation in progress\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eLot number\u003c\/th\u003e\n\u003ctd\u003eHouse lot epi10-0626-01, printed on the vial label — manufacturer batch CS-ep10-0902, which is the number printed on the certificate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eCost per mg\u003c\/th\u003e\n\u003ctd\u003e$5.50 per mg ($54.99 \/ 10 mg)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eStorage\u003c\/th\u003e\n\u003ctd\u003eLyophilised: −20 °C long-term, 2–8 °C short-term, sealed, desiccated and protected from light; warm sealed vial to room temperature before opening to avoid condensation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eRelated compounds\u003c\/th\u003e\n\u003ctd\u003e\n\u003ca href=\"\/products\/mots-c-10mg\"\u003eMOTS-C 10mg\u003c\/a\u003e · \u003ca href=\"\/products\/ghk-cu-50mg\"\u003eGHK-Cu 50mg\u003c\/a\u003e · \u003ca href=\"\/products\/semax-10mg\"\u003eSemax 10mg\u003c\/a\u003e · \u003ca href=\"\/products\/bpc-157-10mg\"\u003eBPC-157 10mg\u003c\/a\u003e · \u003ca href=\"\/products\/tb-500-10mg\"\u003eTB-500 10mg\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eShips from\u003c\/th\u003e\n\u003ctd\u003eBritish Columbia, Canada — free tracked shipping Canada-wide, dispatched within 48 hours\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eRegulatory status\u003c\/th\u003e\n\u003ctd\u003eInvestigational. Not approved by Health Canada, the FDA, the EMA or any other regulator. No DIN. Named in Health Canada's 9 April 2026 peptide advisory\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eIntended use\u003c\/th\u003e\n\u003ctd\u003eLaboratory research only — in vitro and preclinical. Not a drug; not for human or veterinary use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003cth\u003eEvidence grade\u003c\/th\u003e\n\u003ctd\u003ePreliminary \/ hypothesis-generating. Most data from a single research network; key human cohorts used epithalamin (extract), not synthetic Epithalon; no blinded placebo-controlled human trial of the synthetic peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cdetails\u003e\u003csummary\u003eWhat is Epithalon, and what does the AEDG sequence actually do at the molecular level?\u003c\/summary\u003eEpithalon (also spelled Epitalon) is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, commonly abbreviated AEDG. Chemically it is about as plain as a peptide gets: CAS 307297-39-8, formula C14H22N4O9, average mass 390.35 Da, four residues with free N- and C-termini, no amidation, no acylation and no non-natural residues. Two of its four side chains are carboxylic acids (from glutamate and aspartate), so at neutral pH the molecule carries a net negative charge and is strongly hydrophilic — it dissolves readily in water and aqueous buffer. It was designed at the St. Petersburg Institute of Bioregulation and Gerontology as the minimal defined fragment thought to carry the activity of epithalamin, a pineal-gland extract. The honest answer to 'what does it do at the molecular level' is that this is not settled. Khavinson's group proposes that short peptides of this kind act as 'bioregulators' — that AEDG can enter cells and the nucleus and bind specific DNA sequences in the promoter regions of target genes (including the telomerase catalytic subunit hTERT), modulating their expression. That is a mechanistic hypothesis supported mainly by modelling and in-vitro work from the originating group, not a receptor-and-signalling pathway established the way it has been for, say, a GLP-1 agonist. Epithalon has no known conventional receptor. For a research reagent the practical reading is this: AEDG is a small, well-behaved, water-soluble acidic tetrapeptide whose proposed mode of action — direct gene-expression modulation — is exactly the sort of claim that needs independent replication before it is treated as fact. We supply it for in-vitro and preclinical research only.\u003c\/details\u003e\n\u003cdetails\u003e\u003csummary\u003eWhat has actually been published on Epithalon — and how strong is the evidence?\u003c\/summary\u003eLess than the internet implies, and more lopsided. The foundational in-vitro telomere work is real and citable: Khavinson, Bondarev and Butyugov reported that Epithalon induced telomerase activity and lengthened telomeres in human somatic cells (Bull Exp Biol Med 2003;135(6):590-592, PMID 12937682), and a companion paper reported human fetal fibroblasts dividing past the Hayflick limit (2004;137(5):503-506, PMID 15455129). Animal work includes lifespan and tumour studies in flies, mice and rats under different light regimes (e.g. Vinogradova et al., Bull Exp Biol Med 2007;144(6):825-830, PMID 18856211) and chromosome-aberration studies in senescence-prone mice (Rosenfeld et al., 2002;133(3):274-276, PMID 12360351). The widely quoted 'human' data are where care is needed: the long-term cohorts — a coronary-patient geroprotection study with 15-year follow-up (Korkushko et al., Bull Exp Biol Med 2011;151(3):366-369, PMID 22451889) and the melatonin-rhythm work in elderly people and old monkeys (Korkushko et al., Adv Gerontol 2007;20(1):74-85, PMID 17969590) — used epithalamin, the extract, not synthetic Epithalon. Two structural weaknesses run through almost all of it: nearly every study comes from one research network, and no independent group had replicated the central telomere claim for two decades. That changed in 2025, when a team at Brunel University London revisited it in human cell lines (Al-dulaimi et al., Biogerontology 2025;26:178). So the record is genuine, specific and worth citing — but it is concentrated, largely preclinical, and still thin on independent confirmation. Treat it as hypothesis-generating.\u003c\/details\u003e\n\u003cdetails\u003e\u003csummary\u003eWhat does the evidence on Epithalon NOT support?\u003c\/summary\u003eThis is the most important FAQ on the page, and the one most vendor copy omits. (1) No demonstrated anti-aging effect in humans. There is no blinded, placebo-controlled randomised trial of synthetic Epithalon in people — none. The human longevity and melatonin cohorts routinely cited for 'Epithalon' used epithalamin, a crude pineal extract that is a different substance; you cannot attribute their results to AEDG. (2) No established telomere lengthening in living human tissue. The telomerase and telomere-elongation findings are cell-culture results. The 2025 Brunel replication (Al-dulaimi et al., Biogerontology 2025;26:178) is itself 2D cell culture, used cancer and normal cell lines, and its authors explicitly called for 3D and in-vivo work before drawing physiological conclusions — and noted that in cancer lines the elongation appeared to run through the ALT pathway rather than telomerase, which is not the mechanism usually advertised. (3) Melatonin effects are not even consistent in animals: while epithalamin raised melatonin in several reports, at least one study found synthetic Epithalon did NOT stimulate melatonin in rats (Djeridane et al., 2003), a negative result rarely mentioned. (4) No safety profile. There is no published Phase I trial of Epithalon, no pharmacokinetic data in humans, no dosing science, and no long-term toxicology on the synthetic peptide. (5) No approval anywhere, and no evidence that 'research use only' labelling confers any legal or safety assurance. Anyone citing Epithalon for lifespan extension, telomere reversal, or 'reversing biological age' is reaching well past what the data show.\u003c\/details\u003e\n\u003cdetails\u003e\u003csummary\u003eEpithalon vs epithalamin — what is the difference, and why does it matter so much?\u003c\/summary\u003eThey are two different substances, and conflating them is the single most common error in writing about this compound. Epithalamin is the original material: a polypeptide EXTRACT of the bovine (and sometimes ovine) pineal gland, developed by Khavinson's group from the 1970s onward. Being an extract, it is a crude mixture of many peptides whose exact composition can vary from preparation to preparation. Epithalon (Ala-Glu-Asp-Gly) is a SINGLE synthetic tetrapeptide, later proposed as the minimal active fragment responsible for epithalamin's effects — the point of synthesising it was to have one defined molecule instead of a variable mixture. Why it matters: most of the headline 'human evidence' for Epithalon is actually evidence for epithalamin. The lifespan studies in the 1998 Mech Ageing Dev paper (Anisimov, Mylnikov, Khavinson, PMID 9701766) used epithalamin; the 15-year coronary-cohort geroprotection study (Korkushko et al., 2011, PMID 22451889) used epithalamin; the melatonin-rhythm normalisation in elderly people (Korkushko et al., 2007, PMID 17969590) used epithalamin. When a product page cites '12-year human data showing 28% lower mortality,' that figure comes from an epithalamin cohort, not from the synthetic tetrapeptide in the vial. Because epithalamin is a variable mixture, it is also scientifically hard to attribute any specific effect to AEDG alone, and impurities in older synthetic preparations have been floated as one reason in-vitro and in-vivo results sometimes diverge. The clean statement: Epithalon is the defined molecule; epithalamin is the extract; the strongest 'human' claims belong to the extract; and we sell the tetrapeptide, as a reagent, with that distinction stated plainly rather than blurred.\u003c\/details\u003e\n\u003cdetails\u003e\u003csummary\u003eWhat does the telomerase and telomere research actually show, including the 2025 replication?\u003c\/summary\u003eThe original claim, from Khavinson's group: adding Epithalon to cultured human somatic cells induced telomerase activity and lengthened telomeres, and in human fetal fibroblasts let the cultures proliferate past the usual ~34th-passage Hayflick limit toward the ~44th passage (Khavinson et al., Bull Exp Biol Med 2003;135(6):590-592, PMID 12937682; 2004;137(5):503-506, PMID 15455129). For roughly twenty years that result was not independently reproduced, which is why it should never have been quoted as settled. The 2025 replication is the most useful thing to have happened to this compound's evidence base: Al-dulaimi, Thomas, Matta and Roberts (Biogerontology 2025;26:178, DOI 10.1007\/s10522-025-10315-x), working at Brunel University London, tested Epithalon in two breast-cancer lines (21NT, BT474) and in normal IBR.3 fibroblasts and HMEC epithelial cells. They did observe telomere lengthening and increased hTERT expression across cell types — but with an important nuance: in the NORMAL cells the elongation tracked with increased telomerase activity (reported as roughly 4-fold in IBR.3 and ~26-fold in HMEC after three weeks), whereas in the CANCER cells telomerase activity did not significantly rise and the lengthening appeared to run through the ALT (alternative lengthening of telomeres) pathway, evidenced by raised C-circle levels and PML bodies. So the picture is more complicated than 'Epithalon turns on telomerase.' The authors were candid about limits: this is 2D cell culture only; qPCR reports average telomere length, not chromosome-specific effects; PCR-based ALT readouts can overestimate; and their proposed molecular mechanisms were explicitly untested speculation. It is a genuine independent signal that something happens in culture — not evidence of anti-aging in an organism, and the authors did not claim otherwise.\u003c\/details\u003e\n\u003cdetails\u003e\u003csummary\u003eWhat is the pineal gland and melatonin connection, and how solid is it?\u003c\/summary\u003eThe connection is historical and real at the level of origin, and weaker than usually presented at the level of proof. Epithalon descends from epithalamin, an extract of the pineal gland — the organ that secretes melatonin and helps set circadian rhythm — so a pineal\/melatonin framing is where this peptide comes from, and why it is called a 'pineal tetrapeptide bioregulator.' On the evidence: in aged animals and in elderly human cohorts, epithalamin (the extract) was reported to restore the amplitude of nocturnal melatonin and to normalise circadian patterns, including work in old monkeys and elderly people (Korkushko et al., Adv Gerontol 2007;20(1):74-85, PMID 17969590), and the classic lifespan paper attributed epithalamin's effects partly to raised melatonin synthesis (Anisimov, Mylnikov, Khavinson, Mech Ageing Dev 1998;103(2):123-132, PMID 9701766). Two cautions are essential. First, most of that melatonin data again used epithalamin, not synthetic Epithalon. Second, the synthetic peptide itself has a negative result on record: at least one study reported that Epithalon did NOT stimulate melatonin production in rats (Djeridane et al., 2003), which sits awkwardly beside the positive extract data and is almost never cited on product pages. There are also reports that Epithalon may cross into the brain and affect cortical neurons and phospho-CREB in rodents, but these are small, single-network findings. The defensible summary: the pineal\/melatonin story is the reason this peptide exists and is studied, the animal extract data are suggestive, and the specific claim that the synthetic AEDG tetrapeptide restores human melatonin rhythm is not established.\u003c\/details\u003e\n\u003cdetails\u003e\u003csummary\u003eHow does Epithalon compare to MOTS-C and GHK-Cu as a research reagent?\u003c\/summary\u003eAll three get grouped under 'longevity peptides,' but mechanistically they sit in different compartments of the cell and are studied with different assays, so the comparison is about experimental fit, not ranking. Epithalon (AEDG) is a nuclear\/gene-expression-oriented tetrapeptide: the research interest is telomerase, hTERT, telomere length, replicative senescence and pineal\/circadian signalling — the reagent belongs in TRAP assays, qPCR\/TRF telomere measurement, Hayflick-limit culture models and ALT readouts. MOTS-C is a mitochondrial-derived peptide, encoded within the 12S rRNA region of mitochondrial DNA, studied in metabolic and mitochondrial-stress models, AMPK signalling and exercise\/insulin-sensitivity contexts — a fundamentally different organelle and pathway (see our MOTS-C page). GHK-Cu is a copper-binding tripeptide (glycyl-L-histidyl-L-lysine with Cu2+) studied in skin remodelling, wound models, collagen and fibroblast biology and gene-expression modulation (see our GHK-Cu page); it has by far the most independent, non-single-network literature of the three. There is one neat point of overlap worth knowing: Epithalon has itself been reported to affect matrix-metalloproteinase expression in aging fibroblasts, which is squarely GHK-Cu's territory, so a fibroblast-remodelling study could reasonably run both. The decisive practical difference is evidence maturity: GHK-Cu and MOTS-C each have broader independent literature, while Epithalon's base is concentrated in one network and only began to see outside replication in 2025. If a protocol needs a reagent with the deepest independent characterisation, Epithalon is not that reagent; if the protocol is specifically about telomerase or pineal bioregulation, it is the obvious one.\u003c\/details\u003e\n\u003cdetails\u003e\u003csummary\u003eIs Epithalon legal in Canada, and is it prohibited in sport?\u003c\/summary\u003eEpithalon is not an approved medicine in Canada or anywhere else. There is no Health Canada authorisation and no Drug Identification Number (DIN), no FDA approval and no EMA approval; it is investigational. More specifically, Health Canada named 'Epitalon' by that spelling in its public advisory of 9 April 2026, 'Think twice before injecting peptides bought online,' listing it alongside BPC-157, CJC-1295, GHK-Cu, ipamorelin, MOTS-c, TB-500 and others. The advisory states these products have not been assessed by Health Canada for safety, efficacy or quality, that selling them for human use is illegal in Canada, and — the sentence a research-peptide vendor is obliged to reproduce rather than bury — that labelling a product 'For Research Use Only' does NOT make it legal to use in people. It names hormonal disturbance, organ damage, and contamination or inconsistent ingredients among the risks. We sell this vial strictly as a laboratory reagent, not for injection into anyone for any purpose, and an independent certificate addresses only whether the contents match the label — it says nothing about safety in a body, because no such review exists for this compound. On sport: Epithalon is not listed by name on the WADA Prohibited List, and there is no general peptide-bioregulator prohibited class that clearly captures AEDG. We will not translate that into 'permitted,' because WADA's catch-all provisions (such as substances with no current regulatory approval for human therapeutic use, assessed under section S0) can apply to exactly this kind of unapproved investigational compound, and the List is revised annually. Any researcher, athlete or institution with a compliance question should treat an unapproved peptide as high-risk and check the current List directly.\u003c\/details\u003e\n\u003cdetails\u003e\u003csummary\u003eHow is identity and purity verified for each lot, and where is the COA?\u003c\/summary\u003eEvery lot we put on sale is analysed by a third-party laboratory before we treat its figures as real, and the certificate is published openly, with no email gate, so the vial in your hand can be matched to the document. For this Epithalon lot, that certificate is published: lot epi10-0626-01 — manufacturer batch CS-ep10-0902, as printed on the certificate — was assayed by Janoshik Analytical (report #230585, analysed 14 September 2026), returning 99.004% HPLC purity and 11.75 mg content. That assay was commissioned by the manufacturer, not by us, and our own confirmatory Testides test on this lot is still in progress. We do not borrow another lot's numbers to fill the space. The certificate is published on this page and in our lab-results library, and the specification table carries the verified purity, measured content and lot number rather than leaving them blank. The COA carries two distinct measurements that answer two different questions, and you need both: identity, confirmed by mass spectrometry (does the mass match C14H22N4O9 \/ 390.35 Da — is this actually AEDG and not a different or mislabelled peptide?), and purity, by HPLC as an area-percent at a stated UV wavelength (what fraction of the detected material is the target peptide versus truncations, deletion sequences and other peptide-related impurities?). A certificate that does not state its wavelength has not told you what its percentage means, and a purity figure says nothing about how many milligrams are in the vial — that is a separate content measurement. We publish the wavelength, the method and the lot number precisely so the figure can be interrogated rather than taken on faith. For a full walkthrough of what each line on a certificate means, see our guide on how to read a peptide COA.\u003c\/details\u003e\n\u003cdetails\u003e\u003csummary\u003eWhere is this lot's certificate, and what exactly does it cover?\u003c\/summary\u003eThis lot's certificate is published rather than back-dated or borrowed from another lot. Lot epi10-0626-01 was assayed by Janoshik Analytical (report #230585, analysed 14 September 2026), and we show the real figures — 99.004% HPLC purity and 11.75 mg content — rather than an empty purity field. The assay was ordered by the manufacturer, not by us; our own confirmatory Testides test on this lot is still in progress. One thing to expect before you check it: the certificate does not print our house lot. It prints the manufacturer's batch, CS-ep10-0902, while the vial label carries epi10-0626-01. The two identify the same material, and the report itself can be checked with verification key 6NXMK64ULMK2 at janoshik.com\/verify. This is the same standard we hold every lot to — a certificate is only meaningful if it can be matched to the specific vial shipped, and if it is readable without a login. Two further points are worth being explicit about. First, the molecular identifiers on this page (CAS 307297-39-8, formula C14H22N4O9, mass 390.35 Da, PubChem CID 219042, UNII O65P17785G) are compound-level facts that are true of Epithalon as a molecule regardless of lot, and are concordant across PubChem and independent chemical references — they are not lot test results and do not depend on the certificate. Second, the certificate is specifically the identity-and-purity analysis of this lot: mass-spec identity confirmation and HPLC purity at a stated wavelength, with the verified purity, measured content and lot number indexed on our lab-results page. If you want the certificate in hand before purchasing, it is already posted there.\u003c\/details\u003e\n\u003cdetails\u003e\u003csummary\u003eHow should lyophilised Epithalon be stored and handled in the laboratory?\u003c\/summary\u003eAs supplied, Epithalon is a lyophilised (freeze-dried) powder, and the dry powder is the stable form. The research convention for an unformulated short peptide like this is to store the sealed, desiccated vial at −20 °C for long-term holding, 2–8 °C for short-term, protected from light and moisture. One practical habit matters more than it sounds: let a cold sealed vial warm to room temperature BEFORE opening it, so that atmospheric moisture does not condense onto the cold powder and begin hydrolysing it. Sealed vials tolerate ordinary ambient shipping temperatures for the transit period without meaningful loss — the cold requirement is about holding, not the journey. On intrinsic chemical stability, AEDG is in some respects a forgiving molecule and in others not. It has no methionine or cysteine, so the classic methionine-oxidation and disulfide-scrambling degradation routes do not apply, and short peptides are generally robust in the dry state. But it does contain aspartate and glutamate, and aspartate (especially an Asp-Gly motif, which AEDG has at its C-terminus) is a known hotspot for deamidation, isomerisation and succinimide formation in aqueous solution — chemistry that is slow in dry powder and faster once the peptide is wet, warm, or at non-neutral pH. The sensible default for a neat peptide with no excipient and no formal shelf-life study behind it is therefore the conservative one: keep it dry and cold, and validate stability under your own buffer and temperature conditions rather than assuming it. We publish no 'days in solution' figure because no stability study we can verify has been done on reconstituted Epithalon at a defined concentration, buffer and temperature; a supplier quoting a specific number is quoting something they have not measured. This is general handling information for a reagent, not a usage protocol.\u003c\/details\u003e\n\u003cdetails\u003e\u003csummary\u003eHow is Epithalon reconstituted and handled in a research setting?\u003c\/summary\u003eIn the laboratory, water-soluble research peptides like Epithalon are dissolved in sterile water, bacteriostatic water, or an aqueous buffer compatible with the planned assay. AEDG makes this easy: it is a small, acidic, highly hydrophilic tetrapeptide and generally goes into aqueous media readily without needing organic co-solvents or sonication. Because it carries two carboxylic-acid side chains, it is most comfortable at or near neutral pH, and strongly acidic or strongly basic buffers held for long periods will accelerate the aspartate-related degradation chemistry mentioned in the storage FAQ. Beyond that, reconstitution volume, buffer choice, working concentration and assay format depend entirely on the experimental design — a telomerase (TRAP) assay, a long-term fibroblast passage study, and a melatonin or gene-expression readout each impose their own requirements, and in the published cell work concentrations on the order of fractions of a microgram per millilitre to a few micrograms per millilitre have been used. Two general good-practice points apply to any reconstituted peptide and to this one: reconstituted solution is less stable than dry powder, so prepare it close to when it is needed; and divide stock into single-use aliquots at first preparation so that no working volume is subjected to repeated freeze-thaw cycling, which is the most common avoidable cause of peptide loss. Do not return thawed material to the freezer. We stock laboratory bacteriostatic water for reconstitution — see our \u003ca href=\"\/blogs\/research\/bacteriostatic-water-chemistry\"\u003ebacteriostatic water chemistry guide\u003c\/a\u003e. What we do NOT provide — for any compound, and emphatically for this one — is any dosing, administration, or human-use instruction: Epithalon is sold for in-vitro and preclinical research only, and nothing here is a protocol for use in a living subject.\u003c\/details\u003e\n\u003cdetails\u003e\u003csummary\u003eHow fast do you ship, and is delivery free across Canada?\u003c\/summary\u003eShipping is free and tracked, Canada-wide, on every order, with no minimum. Orders are dispatched within 48 hours, Monday to Friday, from our facility in British Columbia. Because the vial is already in Canada there is no international leg, no customs clearance and no import brokerage fee on a domestic order — one of the practical reasons Canadian researchers order domestically rather than from overseas suppliers, where a lyophilised peptide can sit in customs for weeks and arrive with no cold-chain record and an unverifiable chain of custody. Shipping from within the country removes that uncertainty entirely. You receive tracking at dispatch so you can follow the package to delivery, and lyophilised Epithalon tolerates the ambient temperatures of a domestic transit window without meaningful loss, so standard tracked shipping is appropriate and no special cold-pack service is required for the journey. Vials leave sealed with the house lot identifier epi10-0626-01 on the label; this lot's certificate is published and prints the manufacturer batch CS-ep10-0902 for the same material, so the label can be matched against the document before anything is opened. Current transit-time estimates by region are on our shipping page. Dispatch times, tracking and the free-shipping terms are exactly the same as for every other product in the catalogue, and this lot's certificate is already posted on this page.\u003c\/details\u003e\n\u003cdetails\u003e\u003csummary\u003eWhat is your refund policy if a vial arrives damaged?\u003c\/summary\u003eReport damage in transit or non-delivery to info@thepeptide.ca within 48 hours of the expected delivery date, with photographs of the packaging and vial where applicable, and we will resolve it — replacement or refund. The 48-hour window exists because carriers impose their own short claim deadlines on tracked parcels, so prompt reporting, with photographs of the outer packaging and the vial as it arrived, is what lets us act on a damage claim rather than having it time out. Sealed, unopened vials are exchangeable within 14 days of delivery under our standard store policy. There are no refunds or exchanges on product that has been opened, reconstituted or otherwise prepared: once a seal is broken we cannot verify the handling, temperature or light history of the material, and a reagent of unknown provenance — potentially warmed, exposed to light, or partially reconstituted — is not one we will put back into circulation for another researcher, which is a matter of protecting the next buyer's data as much as our own liability. This is a safety-and-integrity position, not a convenience one, and it is standard for research chemicals. If there is any problem with an order — damage, a shortfall against what was ordered, a labelling question, or a concern about this lot's independent certificate and you want to cross-check it against the vial — contact us promptly and we will make it right. Full terms are on our refund policy page.\u003c\/details\u003e","brand":"ThePeptide","offers":[{"title":"Default Title","offer_id":50592979320902,"sku":"EPI-10MG","price":54.99,"currency_code":"CAD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0734\/3020\/4486\/files\/epithalon10-08.png?v=1791516753","url":"https:\/\/thepeptide.ca\/products\/epithalon-10mg","provider":"ThePeptide","version":"1.0","type":"link"}